AB-205 (Artiva Biotherapeutics/GC Cell)

N/A

Report date: 2024/08/15 14:31:52

Base Information

Drug NameAB-205 (Artiva Biotherapeutics/GC Cell)
Drug Alias NameCD5 CAR-NKGCC-2005GL-205GCC2005
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT-cell surface glycoprotein CD5 modulators
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsLymphoma, T-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGC Cell Corp
China Registration ClassN/A

Develop Information

Active CompaniesGC Cell CorpArtiva Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A